Xeris Biopharma Holdings Inc (NASDAQ: XERS) has seen a decline in its stock price by -2.96 in relation to its previous close of 4.90. However, the company has experienced a 6.14% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2025-05-08 that Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q1 2025 Results Conference Call May 8, 2025 8:30 AM ET Company Participants Allison Wey – SVP of IR, Corporate Communications John Shannon – CEO Steve Pieper – CFO Conference Call Participants David Amsellem – Piper Sandler Eason Lee – Leerink Partners Jason Dorr – Oppenheimer Chase Knickerbocker – Craig-Hallum Operator Good morning. Thank you for attending today’s Xeris Biopharma First Quarter 2025 Results Conference Call.
Is It Worth Investing in Xeris Biopharma Holdings Inc (NASDAQ: XERS) Right Now?
Moreover, the 36-month beta value for XERS is 0.70. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for XERS is 147.66M and currently, short sellers hold a 11.67% of that float. On May 14, 2025, XERS’s average trading volume was 3.24M shares.
XERS’s Market Performance
XERS stock saw an increase of 6.14% in the past week, with a monthly gain of 14.30% and a quarterly increase of 32.82%. The volatility ratio for the week is 7.94%, and the volatility levels for the last 30 days are 6.15% for Xeris Biopharma Holdings Inc (XERS). The simple moving average for the last 20 days is 5.90% for XERS stock, with a simple moving average of 34.53% for the last 200 days.
Analysts’ Opinion of XERS
Many brokerage firms have already submitted their reports for XERS stocks, with Piper Sandler repeating the rating for XERS by listing it as a “Neutral.” The predicted price for XERS in the upcoming period, according to Piper Sandler is $3 based on the research report published on November 11, 2024 of the previous year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see XERS reach a price target of $5. The rating they have provided for XERS stocks is “Outperform” according to the report published on March 28th, 2024.
Craig Hallum gave a rating of “Buy” to XERS, setting the target price at $4.50 in the report published on August 28th of the previous year.
XERS Trading at 1.14% from the 50-Day Moving Average
After a stumble in the market that brought XERS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -21.66% of loss for the given period.
Volatility was left at 6.15%, however, over the last 30 days, the volatility rate increased by 7.94%, as shares surge +9.25% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +27.60% upper at present.
During the last 5 trading sessions, XERS rose by +6.81%, which changed the moving average for the period of 200-days by +83.33% in comparison to the 20-day moving average, which settled at $4.49. In addition, Xeris Biopharma Holdings Inc saw 40.27% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at XERS starting from Fairley Ricki Louise, who proposed sale 56,667 shares at the price of $4.90 back on May 09 ’25. After this action, Fairley Ricki Louise now owns shares of Xeris Biopharma Holdings Inc, valued at $277,668 using the latest closing price.
Hecht Beth, the See Remarks of Xeris Biopharma Holdings Inc, sale 40,000 shares at $5.43 during a trade that took place back on Mar 20 ’25, which means that Hecht Beth is holding 1,353,510 shares at $217,244 based on the most recent closing price.
Stock Fundamentals for XERS
Current profitability levels for the company are sitting at:
- -0.17 for the present operating margin
- 0.79 for the gross margin
The net margin for Xeris Biopharma Holdings Inc stands at -0.27. The total capital return value is set at -0.15. Equity return is now at value -617.16, with -13.83 for asset returns.
Based on Xeris Biopharma Holdings Inc (XERS), the company’s capital structure generated 1.12 points at debt to capital in total, while cash flow to debt ratio is standing at -0.14. The debt to equity ratio resting at -9.17. The interest coverage ratio of the stock is -1.1.
Currently, EBITDA for the company is -11.3 million with net debt to EBITDA at -14.28. When we switch over and look at the enterprise to sales, we see a ratio of 4.68. The receivables turnover for the company is 5.02for trailing twelve months and the total asset turnover is 0.63. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.72.
Conclusion
To wrap up, the performance of Xeris Biopharma Holdings Inc (XERS) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
